Table II.
Association between chemotherapeutic effect and clinicopathologic characteristics in 102 patients with TNBC.
| Chemotherapeutic effect | ||||
|---|---|---|---|---|
| Characteristics | pCR (%) | Non-pCR (%) | χ2 | P-value |
| Age (years) | ||||
| ≤50 | 11 (18.3) | 49 (81.7) | 0.291 | 0.589 |
| >50 | 6 (14.3) | 36 (85.7) | ||
| Menstrual status | ||||
| Pre-menopause | 13 (18.6) | 57 (81.4) | 0.583 | 0.445 |
| Post-menopause | 4 (12.5) | 28 (87.5) | ||
| BMI | ||||
| <24 | 5 (7.8) | 59 (92.2) | 9.697 | 0.002 |
| ≥24 | 12 (31.6) | 26 (68.4) | ||
| Family history | ||||
| No | 15 (17.9) | 69 (82.1) | 0.486 | 0.730 |
| Yes | 2 (11.1) | 16 (88.9) | ||
| Tumor grade | ||||
| I–II | 15 (19.7) | 61 (80.3) | 2.023 | 0.226 |
| III | 2 (7.7) | 24 (92.3) | ||
| Tumor size (cm) | ||||
| ≤5 | 10 (14.5) | 59 (85.5) | 0.726 | 0.394 |
| >5 | 7 (21.2) | 26 (78.8) | ||
| Lymph node metastasis | ||||
| No | 6 (16.2) | 31 (83.8) | 0.008 | 0.927 |
| Yes | 11 (16.9) | 54 (83.1) | ||
| Clinical stage | ||||
| I–II | 10 (18.9) | 43 (81.1) | 0.385 | 0.535 |
| III | 7 (14.3) | 42 (85.7) | ||
| AR | ||||
| Negative | 12 (14.6) | 70 (85.4) | 1.244 | 0.316 |
| Positive | 5 (25.0) | 15 (75.0) | ||
| Ki-67 | ||||
| <14 | 3 (13.0) | 20 (87.0) | 0.281 | 0.756 |
| ≥14 | 14 (17.7) | 65 (82.3) | ||
TNBC, triple negative breast cancer; AR, androgen receptor; pCR, pathological complete responses.